Overview

Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects

Status:
NOT_YET_RECRUITING
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the interaction of oral HRS-9813 capsules with pirfenidone and nintedanib on the pharmacokinetics of healthy subjects.
Phase:
PHASE1
Details
Lead Sponsor:
Guangdong Hengrui Pharmaceutical Co., Ltd
Treatments:
pirfenidone